17 results
Thumbnail

- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan

Thumbnail

D3.317 - Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus

Thumbnail

D3.322 - Acquired chronic granulomatous disease secondary to myelodysplastic disorder

Thumbnail

D3.324 - Mastoiditis as complication of Hyper IgM syndrome

Thumbnail

D3.326 - A RARE COEXISTENCE: CARD9 DEFICIENCY AND IgG4-RELATED DISEASE IN A PEDIATRIC PATIENT

Thumbnail

D3.327 - Use of C1 Inhibitor Subcutaneously in the United Kingdom

Thumbnail

D3.328 - Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia

Thumbnail

D3.332 - Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults

Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year